肺动脉高压患者行微创二尖瓣手术安全性的倾向评分匹配分析
该回顾性研究纳入2002至2019年591例孤立性二尖瓣手术的肺动脉高压患者,按全胸骨切开或微创入路分组并行倾向评分匹配。匹配后微创组体外循环、主动脉阻断及总手术时间更长,但初始通气时间和住院时间更短、血制品使用率更低,30天及10年生存率相似。
要点
- 肺动脉高压患者行微创二尖瓣手术安全,未增加30天或远期死亡风险。
- 微创组体外循环、主动脉阻断及总手术时间显著长于全胸骨组。
- 微创组初始通气时间、住院时间更短,血制品使用率更低。
核心结论
- 在肺动脉高压患者中,微创二尖瓣手术安全,并提供微创手术的传统获益,包括更短的初始通气时间和住院时间,且不损害长期生存。
研究设计与样本
- 回顾性研究,纳入2002至2019年所有接受孤立性二尖瓣手术的成人患者,共591例手术(微创317例,全胸骨274例)。
- 将肺动脉高压(平均肺动脉压≥25 mm Hg)患者按全胸骨或微创分组,采用最近邻倾向评分匹配生成112对匹配良好的患者。
主要发现
- 微创组体外循环时间137 vs 89.5分钟(P < .001)、主动脉阻断时间102 vs 63分钟(P < .001)、总手术时间241 vs 178.5分钟(P < .001)均长于全胸骨组。
- 微创组术后初始通气时间6 vs 9.6小时(P < .001)、住院时间7 vs 8天(P = .049)、血制品使用率26.8% vs 41.1%(P = .03)均低于全胸骨组。
- 30天生存率(0.0% vs 2.7%,P = .12)和10年生存率(log-rank,P = .661)两组相似。
临床怎么用
- 对合并肺动脉高压的二尖瓣手术患者,微创入路可作为安全选择,但需预期更长的手术时间。
- 微创入路可能带来更短的术后通气时间和住院时间,并减少血制品使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Compared with conventional full sternotomy (FS) approaches, minimally invasive mitral valve surgery (MIMVS) offers improved cosmesis, decreased pain and bleeding, and faster recovery without compromising repair or survival rates. However, little is known about outcomes in patients with pulmonary hypertension (PH), an independent risk factor for morbidity and mortality. METHODS: Retrospective review was performed between 2002 and 2019 for all adult patients undergoing isolated mitral valve surgery. Patients with PH (mean pulmonary artery pressure ≥25 mm Hg) were stratified by FS or MIMVS, and nearest-neighbor propensity score matching was performed to adjust for differences in baseline characteristics. RESULTS: Overall, 591 operations (317 MIMVS, 274 FS) met inclusion criteria during the study period. Nearest-neighbor propensity matching generated 112 well-matched pairs. Cardiopulmonary bypass (137 vs 89.5 minutes, P < .001), cross-clamp (102 vs 63 minutes, P < .001), and total operative times (241 vs 178.5 minutes, P < .001) were longer for the MIMVS group. Postoperatively, MIMVS was associated with shorter initial ventilator times (6 vs 9.6 hours, P < .001) and hospital lengths of stay (7 vs 8 days, P = .049), as well as blood product usage rates (26.8% vs 41.1%, P = .03). Survival at 30 days (0.0% vs 2.7%, P = .12) and 10 years (log-rank, P = .661) were similar between groups. CONCLUSIONS: MIMVS is safe in patients with PH and provides traditional benefits of minimally invasive surgery, including shorter initial ventilator times and hospital length of stay, without compromising on long-term survival.
引用
- Helmers MR, Kim ST, Altshuler P, et al. Mitral Valve Surgery in Pulmonary Hypertension Patients: Is Minimally Invasive Surgery Safe? Ann Thorac Surg. 2020. PMID: 32991840. doi:10.1016/j.athoracsur.2020.06.147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。